Dapagliflozin fails to improve outcomes in critically ill patients with acute organ dysfunction: DEFENDER Trial findings Medha Baranwal17 Jun 2024 9:00 AM ISTBrazil: In a groundbreaking development for critical care medicine, the DEFENDER trial has unveiled results regarding the use of dapagliflozin in...
AstraZeneca Farxiga gets USFDA nod for paediatric type 2 diabetes Ruchika Sharma14 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) for the improvement of...
Akums Drugs and Pharmaceuticals Gets CDSCO Panel Nod To study Dapagliflozin plus Bisoprolol FDC Dr. Divya Colin12 Jun 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted permission to the...
Applicability of FDC of Linagliptin and Dapagliflozin in T2DM: EVERGREEN Case Report Summaries Dr Jeegar Dattani24 May 2024 11:00 AM ISTThe EVERGREEN webinar, designed to guide physicians regarding the care of people with diabetes, highlighted the clinical applicability of a...
Dapagliflozin promising in providing nephroprotectin in children with CKD, reveals study Jacinthlyn Sylvia14 May 2024 7:30 AM ISTA retrospective single-center study published in the American Journal of Nephrology highlighted a potential treatment in pediatric chronic kidney...
Bexagliflozin found as effective as dapagliflozin for glycemic control in diabetes: Study Medha Baranwal11 April 2024 9:30 AM ISTChina: A 24-week, phase 3 trial has shed light on the safety and efficacy of bexagliflozin versus dapagliflozin as an adjunct to metformin in Chinese...
Pioglitazone add-on therapy in patients with type 2 diabetes effective and safe option for better glycemic control: Study Medha Baranwal10 April 2024 10:00 AM ISTSouth Korea: Adjunctive pioglitazone therapy in type 2 diabetes mellitus (T2DM) inadequately controlled with dapagliflozin and metformin yielded...
Evergreen Talk Series: How can Safety and Tolerability of Linagliptin and Dapagliflozin benefit diverse T2DM population? MD Brand Connect25 March 2024 4:38 PM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
Finerenone and dapagliflozin combo significantly reduced albuminuria in non-diabetic CKD patients: Study Aditi20 March 2024 7:30 PM ISTThe effectiveness of dapagliflozin and finerenone in reducing albuminuria and slowing the progression of chronic kidney disease (CKD) has been...
Synokem gets CDSCO Panel Nod To Study FDC Dapagliflozin plus Sacubitril plus Valsartan Dr. Divya Colin10 March 2024 5:30 PM ISTNew Delhi: The drug major Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
AstraZeneca gets CDSCO Panel Nod To update Prescribing Information of Antidiabetic FDC Dr. Divya Colin7 March 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
